Gossamer Bio Faces Legal Storm After Clinical Trial Setback

Gossamer Bio's seralutinib fails Phase 3 trial, triggering class-action lawsuits and an 88% stock crash. The company now battles legal and financial pressures.

The biopharmaceutical firm Gossamer Bio finds itself navigating a perfect storm of legal challenges and investor skepticism. This follows the disappointing outcome of a pivotal late-stage clinical trial for its lead drug candidate, seralutinib. Multiple law firms have now initiated class-action lawsuits, alleging the company misled shareholders about the drug's prospects in the treatment of pulmonary arterial hypertension (PAH).

A Statistical Threshold Proves Fatal

At the heart of the controversy is the Phase 3 PROSERA trial. While Gossamer Bio had previously expressed confidence in seralutinib's potential, the study ultimately failed to meet its primary endpoint. This was a statistically significant improvement in the six-minute walk distance for PAH patients. Although the data showed a p-value of 0.032, it did not cross the pre-specified significance threshold of 0.025 required for success. The legal complaints center on accusations that the company inadequately disclosed these stringent statistical hurdles, thereby inflating investor expectations.

Shareholder Value Evaporates

The market's reaction to the February 23, 2026, announcement was swift and severe. Gossamer Bio's share price collapsed from $2.13 to a mere $0.42 in a single session. The equity has continued to struggle, currently trading around $0.36. This represents a staggering loss of over 88% of its value since the start of the year. With its market capitalization now standing at just $74 million, investor confidence appears thoroughly eroded. The stock's 52-week high of $3.87 seems a distant memory.

Mounting Legal and Financial Pressures

Leading the legal charge are firms including Gainey McKenna & Egleston and Holzer & Holzer. They are seeking to represent investors who purchased Gossamer Bio shares between June 2025 and February 2026. The deadline to file as a lead plaintiff in these actions is June 1, 2026.

The company's path forward is fraught with difficulty. Analyst opinions are divided, with the average price target sitting at $5.43, yet recent operational losses of $163 million underscore a precarious financial position. Gossamer Bio must now contend not only with a highly competitive PAH treatment landscape but also with the substantial costs and distractions of ongoing litigation.